PAGANELLI, Giovanni
 Distribuzione geografica
Continente #
NA - Nord America 9.148
EU - Europa 2.706
AS - Asia 1.377
SA - Sud America 11
OC - Oceania 7
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.258
Nazione #
US - Stati Uniti d'America 9.136
PL - Polonia 1.262
CN - Cina 634
TR - Turchia 322
IT - Italia 310
UA - Ucraina 276
SE - Svezia 252
DE - Germania 228
SG - Singapore 205
GB - Regno Unito 198
VN - Vietnam 82
ID - Indonesia 48
IE - Irlanda 48
RU - Federazione Russa 24
FR - Francia 20
KR - Corea 19
JO - Giordania 18
BE - Belgio 15
RO - Romania 14
HK - Hong Kong 13
IN - India 13
NL - Olanda 13
AU - Australia 7
BR - Brasile 7
CA - Canada 7
FI - Finlandia 7
AT - Austria 6
CZ - Repubblica Ceca 6
PT - Portogallo 6
GR - Grecia 5
JP - Giappone 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
CH - Svizzera 3
DK - Danimarca 3
IR - Iran 3
MX - Messico 3
MY - Malesia 3
SC - Seychelles 3
CY - Cipro 2
EU - Europa 2
PE - Perù 2
PH - Filippine 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CO - Colombia 1
DZ - Algeria 1
EC - Ecuador 1
ES - Italia 1
GE - Georgia 1
GL - Groenlandia 1
HR - Croazia 1
HU - Ungheria 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
PA - Panama 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 13.258
Città #
Fairfield 1.499
Warsaw 1.259
Woodbridge 1.181
Ashburn 823
Houston 752
Seattle 605
Chandler 551
Jacksonville 495
Wilmington 495
Cambridge 486
Ann Arbor 380
Izmir 297
Princeton 183
Nanjing 170
Singapore 119
Milan 114
San Diego 106
Boardman 100
Beijing 95
Dearborn 94
Dong Ket 82
Menlo Park 69
Nanchang 67
Ferrara 52
Jakarta 46
Hebei 45
London 43
Falls Church 42
Shenyang 36
Mountain View 30
Tianjin 29
Bologna 28
Jiaxing 25
Changsha 24
Kunming 24
Redwood City 24
Shanghai 24
Norwalk 22
Washington 22
Orange 19
Scottsdale 16
Brussels 15
Fuzhou 14
Addison 13
Jinan 13
Seongnam 13
New York 12
Bremen 11
Rome 10
Tappahannock 10
Hong Kong 9
Indiana 9
Phoenix 9
Zhengzhou 9
Chicago 8
Hefei 8
Hounslow 8
Kilburn 8
Poggio Renatico 8
Helsinki 7
Lanzhou 7
Los Angeles 7
Simi Valley 7
Changchun 6
Dublin 6
Forlimpopoli 6
Guangzhou 6
Putian 6
Redmond 6
Walnut 6
Castenaso 5
Edinburgh 5
Pune 5
San Mateo 5
Seoul 5
Vienna 5
Cesena 4
Council Bluffs 4
Ilmenau 4
Monmouth Junction 4
Rio De Janeiro 4
Tokyo 4
Amsterdam 3
Frankfurt am Main 3
Hangzhou 3
Lelystad 3
Lisbon 3
Mcallen 3
Mulhouse 3
Philadelphia 3
Sofia 3
Wandsworth 3
Yellow Springs 3
Ardabil 2
Arezzo 2
Athens 2
Bari 2
Belgrade 2
Boston 2
Bresso 2
Totale 10.931
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 348
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 284
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 207
Development of sentinel node localization and ROLL in breast cancer in Europe 200
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 198
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 191
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 186
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 180
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 176
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 163
A novel radioguided surgery technique exploiting β- decays 161
Early use of abiraterone and radium-223 in metastatic prostate cancer 157
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 154
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 152
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 148
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 133
Radioimmunotherapy in brain tumors 131
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 122
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 119
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 119
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 117
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 111
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 109
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 107
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 104
Sentinel lymph node biopsy in pregnant patients with breast cancer 101
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 101
Yttrium-labelled peptides for therapy of NET 101
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 100
Long-term results of PRRT in advanced bronchopulmonary carcinoid 100
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 100
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 99
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 99
Neuroendocrine tumors 98
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 98
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 97
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 97
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 97
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 96
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 95
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 95
OXavidin for tissue targeting biotinylated therapeutics 94
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 94
Yttrium-based therapy for neuroendocrine tumors 94
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 94
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 93
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 93
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 93
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 92
Hibernoma mimicking metastasis on positron emission tomography-computed tomography imaging: A misleading finding in oncologic patient follow-up 92
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 92
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 92
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 91
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 91
PET imaging of HER-2-positive tumours 90
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 90
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 90
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 90
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 90
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 89
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 89
Preoperative FDG PET/CT in breast cancer patients: Where are we going? 88
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 88
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 87
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 87
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 87
Hematologic toxicity and double autografting of stem cells after myeloablative activities of Yttrium-90-Ibritumomab tiuxetan 86
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 85
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 85
PET/CT and breast cancer subtypes 85
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 85
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 85
Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 84
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 84
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL) 84
A parathyroid carcinoma within a cold thyroid nodule 84
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans 84
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 84
Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas 83
An unusual breast lesion: The ultrasonographic, mammographic, MRI and nuclear medicine findings of mammary hibernoma 83
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case 83
Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases 82
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 81
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 81
Positron emission tomography for the detection of colorectal adenomas 80
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application 79
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 79
Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules 78
Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer 78
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 78
Something more than estimating renal dosimetry 77
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 77
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 77
Prostate-specific membrane antigen and renal cell carcinoma: A new diagnostic and therapeutic target? 77
Therapeutic schemes in 177Lu and 90Y-PRRT: Radiobiological considerations 76
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 76
Carcinoma, tuberculosis and elastofibroma in one patient: is [18F]FDG-PET/CT helpful? 75
Sentinel node detection in pre-operative axillary staging 75
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 74
Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues 74
Totale 10.659
Categoria #
all - tutte 68.705
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.527
Totale 71.232


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.063 616 191 183 578 335 450 405 338 345 238 274 110
2020/20212.527 106 174 139 228 178 422 132 309 86 315 180 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/202548 48 0 0 0 0 0 0 0 0 0 0 0
Totale 13.792